

AMENDMENTS TO THE SPECIFICATION

Please insert the following on page 1, after the title:

SEQUENCE LISTING

The instant application contains a Sequence Listing which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on March 30, 2011, is named 86039015.txt and is 121,326 bytes in size.

Please delete the paragraph on page 8, line 16 to page 9, line 4 and replace it with the following paragraph:

Examples of the auxiliary amino acid sequence (Y) include sequences having a (Gly Ala)a (SEQ ID NO: 55) sequence, a (Gly Ala Gly Ala Gly Ser)b (SEQ ID NO: 56) sequence, a (Gly Ala Gly Ala Gly Tyr)c (SEQ ID NO: 57) sequence, a (Gly Ala Gly Val Gly Tyr)d (SEQ ID NO: 58) sequence, a (Gly Ala Gly Tyr Gly Val)e (SEQ ID NO: 59) sequence, an (Asp Gly Gly (Ala)f Gly Gly Ala)g (SEQ ID NO: 60) sequence, a (Gly Val Pro Gly Val)h (SEQ ID NO: 61) sequence, a (Gly)i (SEQ ID NO: 62) sequence, an (Ala)j (SEQ ID NO: 63) sequence, a (Gly Gly Ala)k (SEQ ID NO: 64) sequence, a (Gly Val Gly Val Pro)m (SEQ ID NO: 65) sequence, a (Gly Pro Pro)n (SEQ ID NO: 66) sequence, a (Gly Ala Gln Gly Pro Ala Gly Pro Gly)o (SEQ ID NO: 67) sequence, a (Gly Ala Pro Gly Ala Pro Gly Ser Gln Gly Ala Pro Gly Leu Gln)p (SEQ ID NO: 68) sequence, and/or a (Gly Ala Pro Gly Thr Pro Gly Pro G[[I]])In Gly Leu Pro Gly Ser Pro)q (SEQ ID NO: 69) sequence. Among these, preferred are sequences having a (Gly Ala)a (SEQ ID NO: 55) sequence, a (Gly Ala Gly Ala Gly Ser)b (SEQ ID NO: 56) sequence, a (Gly Ala Gly Ala Gly Tyr)c (SEQ ID NO: 57) sequence, a (Gly Ala Gly Val Gly Tyr)d (SEQ ID NO: 58) sequence, a (Gly Ala Gly Tyr Gly Val)e (SEQ ID NO: 59) sequence, a (Asp Gly Gly (Ala)f Gly Gly Ala)g (SEQ ID NO: 60) sequence, a (Gly Val Pro Gly Val)h (SEQ ID NO: 61) sequence, a (Gly Val Gly Val Pro)m (SEQ ID NO: 65) sequence, and/or a (Gly Pro Pro)n (SEQ ID NO: 66) sequence, more preferred are sequences having a (Gly Ala Gly Ala Gly Ser)b (SEQ ID NO: 56) sequence, a (Gly Val Pro Gly Val)h (SEQ ID NO: 61) sequence, a (Gly Val Gly Val Pro)m (SEQ ID NO: 65) sequence, and/or a (Gly Pro Pro)n (SEQ ID NO: 66) sequence, and particularly preferred are sequences having a (Gly Ala Gly Ala Gly Ser)b (SEQ ID NO: 56) sequence.

Please delete the paragraph on page 10, lines 5-6 and replace it with the following paragraph:

The auxiliary amino acid sequence having a (G[[I]]ly)i (SEQ ID NO: 62) sequence includes amino acid sequences represented by SEQ ID NOs: 31 to 33.

Please delete the paragraphs on page 10, lines 15-22 and replace them with the following paragraphs:

The auxiliary amino acid sequence having a (Gly Ala G[[I]]ln Gly Pro Ala Gly Pro G[[I]]ly)o (SEQ ID NO: 67) sequence includes amino acid sequences represented by SEQ ID NOs: 46 to 48.

The auxiliary amino acid sequence having a (Gly Ala Pro Gly Ala Pro Gly Ser G[[I]]ln Gly Ala Pro Gly Leu G[[I]]ln)p (SEQ ID NO: 68) sequence includes amino acid sequences represented by SEQ ID NOs: 49 to 51.

The auxiliary amino acid sequence having a (G[[i]]ly Ala Pro G[[i]]ly Thr Pro Gly Pro G[[I]]ln Gly Leu Pro Gly Ser Pro)q (SEQ ID NO: 69) sequence includes amino acid sequences represented by SEQ ID NOs: 52 to: 54.

Please delete the paragraph on page 12, lines 20-30 and replace it with the following paragraph:

Moreover, in addition to the polypeptides of (1) to (3), there may be also preferably used RetroNectin (recombinant human fibronectin CH-296) manufactured by Takara (a polypeptide of about 60,000 Mn having an Arg Gly Asp (SEQ ID NO: 70) sequence (xl) and a Leu Asp Val (SEQ ID NO: 73) sequence as the minimum amino acid sequence (X», and RGDS-Protein A ("**RGDS" disclosed as SEQ ID NO: 75**) manufactured by Takara (a polypeptide of about 30,000 Mn having an Arg Gly Asp (SEQ ID NO: 70) sequence (xl) as the minimum amino acid sequence (X), where these polypeptides do not contain an auxiliary amino acid sequence (Y). Therefore, the thermal resistance and the like thereof are inferior to those of the abovementioned (1) to (3).

Moreover, the amino acid sequences of these polypeptides are disclosed in Japanese Unexamined Patent Publication No. H2-311498 (the contents of US5198423A are incorporated in the present application by reference).